20 Posts Not To Miss From ESMOBreast24!
ESMO Breast Cancer 2024 (ESMOBreast24) took place as an onsite and online event in Berlin, Germany, on 15-17 May 2024. It aimed to deliver a comprehensive overview of all the practice-changing new data and ensured a clear roadmap to the clinic.
Our team at OncoDaily compiled the most important posts you should not miss from the event.
Chairs kick off ESMOBreast24. By the numbers:
- 3381 Participants
- 2700 onsite in Berlin
- 620 submitted abstracts
- 6 Proffered Papers
- 17 Mini Oral presentations
- 256 Posters
- 1 Amazing Conference
Truly stimulating discussion by P.A. Fasching in the first Mini Oral Session at ESMOBreast24:
- the GOOD: drivers of efficacy
- the BAD: mechanisms of resistance
- the UGLY: toxicity
I am excited to present the BRIDGES study at ESMOBreast24 -showing the practice patterns and knowledge about IBC in low—and middle-income countries!
Big congratulations to Vasily Giannakeas, recent postdoc fellow at Women’s College Hospital, for winning a Best Poster Award at ESMOBreast24!
Presenting our work on 20-year cumulative risk of breast cancer death after BCS, unilateral mastectomy vs bilateral mastectomy. Manuscript in press!”
Rupert Bartsch delivers a sobering reminder:
Although we can DELAY brain metastasis with better systemic therapy, if we look at trials we aren’t really PREVENTING brain metastasis
Congratulations to Dr. Hope Rugo, recipient of the 2024 ESMO Breast Cancer Award.
Liquid biopsy has not been shown to improve outcome in early breast cancer. I have seen many for 2nd opinions with EBC and tumor markers and/or ctDNA sent by their doctors.
There is harm in the form of (currently non-actionable) worry. Is there benefit? We don’t know.
At ESMOBreast24: In a Danish population-based cohort: study statin use decreases breast cancer mortality. Validation in prospective randomized trials is needed. A phase 3 trial is ongoing.
Professor Sibylle Loibl tackles the exciting and challenging topic of the future of IO in breast cancer : combinations and beyond.
ESMOBreast24 TIP poster PREcoopERA trial for premenopausal women with early breast cancer: is OFS necessary when giving an oral SERD?
DatoDXd vs. chemo in TROPIONBr01. Overall G3 adverse effects half that of chemo with dato.
- stomatitis, ~50%, onset ~ 3 weeks. Still? what percent got steroid prophylaxis
- ocular events, ~40%, most G1
- Nausea and alopecia increase with dato
- neuropathy decreases compared with chemo
More than proud about the ‘best poster’ prize at ESMOBreast24!
Jo Taylor, I missed you here! We put our hearts and souls in this project about platitudes the metastatic breast cancer community has to deal with.
Thank you European Society for Medical Oncology for this recognition!
TROPIONBreast01: While adverse effects, G1/G2, they are annoying and persistent (dry eye, stomatitis) and occurred on “highly recommended” support (steroid mouth wash, eye drops).
Whereas with neutropenia, after dose modification is likely isolated AE. We need better supportive care.
Axillary management in the post-neoadjuvant setting: Local therapy, prognostic information and quality of life. Addressing lymphedema is very important regarding QoL. Great session.
At ESMOBreast24, we presented our poster exploring histologic subtypes of early breast cancers in a large (n>4,600 ) real-world cohort of young women with gBRCAmut and EBC.
Low incidence of lobular histology (3%), associated with BRCA2 PVs; no impact on prognosis.
Theodoros Foukakis presents PANTHER study follow up of DD chemo vs. q 3 weeks.
15 weeks in both arm, But more cycles of chemo in DD arm (4 cycles vs. 3!) and regimens not the same (dd EC-D vs. FEC-D)? Not sure adding 5-FU equals more anthra/tax.
BCRFS 3.7% higher with DD chemo.
Assisted reproductive techniques to have a pregnancy seem to be safe in breast cancer survivors with BRCA1/2 mutation, with no worsening of patients’ prognosis or fetal outcomes.
Brilliant presentation by Matteo Lambertini at ESMOBreast24!
Dr Elise Dumas on vaginal estrogen after an early stage BC diagnosis. I think some of these findings would be applicable to MBC – as we live longer we may want to have functioning vaginas! But, if on an AI, recurrence risks were slightly raised.
The ESMOBreast24 has come to an end. I had a wonderful time meeting and interacting with the BCSM community. Congratulations to the organisers for such a wonderful conference.
What a super ESMOBreast24…3 days of science, progress, education, collaboration and friendship…really proud of our University of Genova dream team and so grateful to ESMO and staff for such an incredible event!
